Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 13/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 4/20 | 0.52 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29165194 | 0.94 | TAS2R14 (0.64) | TAS2R14HSD11B1CNR2POLBCNR1 | |
| SCHEMBL25702585 | 0.83 | TAS2R14 (0.62) | TAS2R14HSD11B1POLBTSHR | |
| SCHEMBL31455664 | 0.83 | MAPT (0.59) | TAS2R14CNR2CNR1PTGES | |
| SCHEMBL30657622 | 0.79 | TAS2R14 (0.61) | TAS2R14HSD11B1CNR2POLBCNR1 | |
| SCHEMBL6966682 | 0.79 | POLB (0.62) | TAS2R14HSD11B1CNR2POLBCNR1 | |
| SCHEMBL25984793 | 0.79 | HSD11B1 (0.81) | TAS2R14HSD11B1CNR2POLBCNR1 | |
| SCHEMBL27864280 | 0.79 | CNR2 (0.58) | TAS2R14CNR2CNR1TSHRHTT | |
| SCHEMBL29165187 | 0.78 | CNR2 (0.60) | TAS2R14HSD11B1CNR2POLBCNR1 | |
| SCHEMBL29165498 | 0.78 | TAS2R14 (0.60) | TAS2R14HSD11B1CNR2POLBCNR1 | |
| SCHEMBL9302981 | 0.78 | NR1H3 (0.61) | TAS2R14CNR2CNR1TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | TAS2R14 4845/4885HSD11B1 4168/4885CNR2 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.